Pyrroloquinoline Quinone (PQQ) Dosing Information
There are no established FDA-approved therapeutic or maximum daily doses for pyrroloquinoline quinone (PQQ), as it is classified as a dietary supplement rather than a pharmaceutical drug, and the available evidence does not support specific dosing recommendations or divided-dose schedules.
Critical Context
The evidence provided contains no guidelines or drug labels specifically addressing PQQ dosing. The references 1 and 1 appear to be FDA drug labels for quinine sulfate (QUALAQUIN) for malaria treatment, not PQQ. This is a critical distinction—quinine and PQQ are entirely different compounds with different uses.
Available Research Evidence on PQQ
Based on the limited research studies provided:
Studied Doses in Humans
- Study 1 2: Single dose of 0.2 mg/kg (approximately 14-16 mg for a 70-80 kg adult)
- Study 2 2: Daily dose of 0.3 mg/kg for 76 hours (approximately 21-24 mg for a 70-80 kg adult)
- General reference 3: Suggests a baseline intake level of 20 mg/day
- Exercise study 4: Used 20 mg PQQ as a single pre-exercise dose
Dosing Frequency
None of the research studies examined or recommended BID or TID dosing schedules. All human studies used:
- Single daily doses
- Single pre-intervention doses
- No evidence supports dividing PQQ into multiple daily doses
Important Caveats
Regulatory Status
- PQQ was approved as a "new food ingredient" by the FDA in 2008 3
- It is approved as a food in Japan and the EU 3
- It is NOT an FDA-approved drug with established therapeutic dosing
Evidence Limitations
- No high-quality guidelines exist for PQQ dosing
- Human studies are limited to small trials (n=10 in 2, n=60 in 4)
- No maximum safe dose has been formally established through systematic toxicology studies
- Long-term safety data in humans are lacking
Clinical Application
Given the absence of regulatory approval as a therapeutic agent and lack of established dosing guidelines, PQQ should be considered an investigational supplement rather than a medical treatment 5. The research suggests doses around 20 mg daily appear safe in short-term studies, but this does not constitute a therapeutic recommendation for clinical practice.
If considering PQQ supplementation, a single daily dose of 20 mg (based on available human research) would be more evidence-based than divided dosing, though neither approach has been validated for therapeutic efficacy.